🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

RecruitingPhase 3Ages 18 Years - anyAllMerck Sharp & Dohme LLC
NCT07405164 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Researchers are looking for new ways to treat advanced solid tumors and von Hippel-Lindau (VHL)-related tumors: * Advanced means the cancer has spread to other parts of the body (metastatic) or cannot be removed with surgery * Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids * VHL-related tumors are tumors caused by VHL disease. VHL disease is passed down from parents to children and people with VHL disease have a higher chance of getting certain types of cancer Researchers want to learn about the long-term effects of a trial medicine called belzutifan. Belzutifan, also called MK-6482, is designed to block a protein that helps tumors grow and survive. This is an extension trial, which means only people who were in certain other belzutifan trials (called parent trials) may be able to join. The goal of this trial is to learn how long peop

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Participants with advanced solid tumors or von Hippel-Lindau-related neoplasms who are participating in belzutifan-containing studies and on active treatment in a belzutifan parent study. Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has an on-going serious adverse event in the parent study, unless no longer hospitalized and considered clinically stable. * Is currently on a dose interruption due to an Adverse Event (AE) in the parent study; once treatment has been resumed in the parent study, the participant is eligible to enroll.
💊

What it tests

  • Belzutifan
  • Nivolumab
  • Lenvatinib
  • Cabozantinib
📍

Where

57 sites
Beth Israel Deaconess Medical Center ( Site 0107)
Boston, United States
Dana-Farber Cancer Institute ( Site 0105)
Boston, United States
Karmanos Cancer Center ( Site 0108)
Detroit, United States
Hospital of the University of Pennsylvania Perelman Center for Advanced Medicine ( Site 0100)
Philadelphia, United States
UPMC Hillman Cancer Center ( Site 0101)
Pittsburgh, United States
SCRI Oncology Partners ( Site 7000)
Nashville, United States
START San Antonio ( Site 0104)
San Antonio, United States
Fred Hutchinson Cancer Center ( Site 0106)
Seattle, United States

…and 49 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy